Monitoring clinical trials: issues and controversies regarding confidentiality
- 20 September 2002
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 21 (19), 2843-2851
- https://doi.org/10.1002/sim.1288
Abstract
During phase III clinical trials in life-threatening disease settings, it is important to ensure that the Data Monitoring Committee (DMC) has exclusive access to the interim efficacy and safety data generated by the data analysis centre, in order to minimize the risk of widespread prejudgement of unreliable trial results based on limited data. This prejudgement could adversely impact rates of patient accrual, continued adherence to trial regimens and ability to obtain unbiased and complete assessment of trial outcome measures. This also could result in publications of early results that might be very inconsistent with final study data on the benefit-to-risk profile of the study interventions. Circumstances arise only rarely in which unblinding of interim data beyond the DMC would enhance the ability of the trial to provide reliable results. However, to address the ethical imperative to protect the interests of study participants, the DMC itself should have access to unblinded efficacy and safety results. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 13 references indexed in Scilit:
- Masked Monitoring in Clinical Trials — Blind Stupidity?New England Journal of Medicine, 1998
- A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individualsAIDS, 1998
- Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDSNew England Journal of Medicine, 1996
- The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trialsControlled Clinical Trials, 1995
- A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1994
- Monitoring of clinical trials: Issues and recommendationsControlled Clinical Trials, 1993
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991
- Organization, review, and administration of cooperative studies (greenberg report): A report from the heart special project committee to the National Advisory heart council, May 1967Controlled Clinical Trials, 1988
- Policies for study monitoring and interim reporting of results.Journal of Clinical Oncology, 1987
- The evaluation of low dose pre-operative X-ray therapy in the management of operable rectal cancer; results of a randomly controlled trialBritish Journal of Surgery, 1984